The basic idea of displaying peptides on a phage, introduced by George P. Smith in 1985, was greatly developed and improved by McCafferty and colleagues at the MRC Laboratory of Molecular Biology and, later, by Barbas and colleagues at the Scripps Research Institute. Their approach was dedicated to building a system for the production of antibodies, similar to a na？ve B cell repertoire, in order to by-pass the standard hybridoma technology that requires animal immunization. Both groups merged the phage display technology with an antibody library to obtain a huge number of phage variants, each of them carrying a specific antibody ready to bind its target molecule, allowing, later on, rare phage (one in a million) to be isolated by affinity chromatography. Here, we will briefly review the basis of the technology and the therapeutic application of phage-derived bioactive molecules when addressed against key players in tumor development and progression: growth factors and their tyrosine kinase receptors.
Davies, D.R.; Cohen, G.H. Interactions of protein antigens with antibodies. Proc. Natl. Acad. Sci. USA 1996, 93, 7–12.
[3]
Skerra, A.; Pluckthun, A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988, 240, 1038–1041.
[4]
Orlandi, R.; Gussow, D.H.; Jones, P.T.; Winter, G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 1989, 86, 3833–3837.
Barbas, C.F., 3rd; Kang, A.S.; Lerner, R.A.; Benkovic, S.J. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc. Natl. Acad. Sci. USA 1991, 88, 7978–7982.
[7]
Watkins, N.A.; Ouwehand, W.H. Introduction to antibody engineering and phage display. Vox Sang 2000, 78, 72–79.
[8]
Engberg, J.; Andersen, P.S.; Nielsen, L.K.; Dziegiel, M.; Johansen, L.K.; Albrechtsen, B. Phage-display libraries of murine and human antibody Fab fragments. Mol. Biotechnol 1996, 6, 287–310.
[9]
Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol 1991, 222, 581–597.
Georgieva, Y.; Konthur, Z. Design and screening of M13 phage display cDNA libraries. Molecules 2011, 16, 1667–1681.
[12]
Iannolo, G.; Minenkova, O.; Petruzzelli, R.; Cesareni, G. Modifying filamentous phage capsid: Limits in the size of the major capsid protein. J. Mol. Biol 1995, 248, 835–844.
[13]
Pande, J.; Szewczyk, M.M.; Grover, A.K. Phage display: Concept, innovations, applications and future. Biotechnol. Adv 2010, 28, 849–858.
[14]
Sidhu, S.S. Engineering M13 for phage display. Biomol. Eng 2001, 18, 57–63.
[15]
Azzazy, H.M.; Highsmith, W.E., Jr. Phage display technology: Clinical applications and recent innovations. Clin. Biochem 2002, 35, 425–445.
[16]
Holliger, P.; Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol 2005, 23, 1126–1136.
[17]
Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134.
[18]
Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70.
[19]
Cheng, N.; Chytil, A.; Shyr, Y.; Joly, A.; Moses, H.L. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol. Cancer Res 2008, 6, 1521–1533.
[20]
Bhowmick, N.A.; Neilson, E.G.; Moses, H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432, 332–337.
[21]
Forbes, S.A.; Tang, G.; Bindal, N.; Bamford, S.; Dawson, E.; Cole, C.; Kok, C.Y.; Jia, M.; Ewing, R.; Menzies, A.; et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010, 38, D652–D657.
[22]
Takahashi, J.A.; Fukumoto, M.; Igarashi, K.; Oda, Y.; Kikuchi, H.; Hatanaka, M. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J. Neurosurg 1992, 76, 792–798.
[23]
Humphrey, P.A.; Gangarosa, L.M.; Wong, A.J.; Archer, G.E.; Lund-Johansen, M.; Bjerkvig, R.; Laerum, O.D.; Friedman, H.S.; Bigner, D.D. Deletion-mutant epidermal growth factor receptor in human gliomas: Effects of type II mutation on receptor function. Biochem. Biophys. Res. Commun 1991, 178, 1413–1420.
[24]
Libermann, T.A.; Nusbaum, H.R.; Razon, N.; Kris, R.; Lax, I.; Soreq, H.; Whittle, N.; Waterfield, M.D.; Ullrich, A.; Schlessinger, J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313, 144–147.
[25]
Jenny, B.; Harrison, J.A.; Baetens, D.; Tille, J.C.; Burkhardt, K.; Mottaz, H.; Kiss, J.Z.; Dietrich, P.Y.; de Tribolet, N.; Pizzolato, G.P.; et al. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J. Pathol 2006, 209, 34–43.
[26]
Baselga, J.; Arteaga, C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol 2005, 23, 2445–2459.
[27]
Seiwert, T.Y.; Jagadeeswaran, R.; Faoro, L.; Janamanchi, V.; Nallasura, V.; El Dinali, M.; Yala, S.; Kanteti, R.; Cohen, E.E.; Lingen, M.W.; et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009, 69, 3021–3031.
[28]
Marshall, M.E.; Hinz, T.K.; Kono, S.A.; Singleton, K.R.; Bichon, B.; Ware, K.E.; Marek, L.; Frederick, B.A.; Raben, D.; Heasley, L.E. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin. Cancer Res 2011, 17, 5016–5025.
Zhao, Z.S.; Zhou, J.L.; Yao, G.Y.; Ru, G.Q.; Ma, J.; Ruan, J. Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J. Gastroenterol 2005, 11, 3227–3233.
[31]
Barclay, C.; Li, A.W.; Geldenhuys, L.; Baguma-Nibasheka, M.; Porter, G.A.; Veugelers, P.J.; Murphy, P.R.; Casson, A.G. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res 2005, 11, 7683–7691.
[32]
Spratlin, J.L.; Cohen, R.B.; Eadens, M.; Gore, L.; Camidge, D.R.; Diab, S.; Leong, S.; O’Bryant, C.; Chow, L.Q.; Serkova, N.J.; et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol 2010, 28, 780–787.
[33]
Gao, J.; Inagaki, Y.; Song, P.; Qu, X.; Kokudo, N.; Tang, W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol. Res 2012, 65, 23–30.
[34]
Golan, T.; Javle, M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park) 2011, 25.
[35]
Reidy, D.L.; Vakiani, E.; Fakih, M.G.; Saif, M.W.; Hecht, J.R.; Goodman-Davis, N.; Hollywood, E.; Shia, J.; Schwartz, J.; Chandrawansa, K.I. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol 2010, 28, 4240–4246.
[36]
Essapen, S.; Thomas, H.; Green, M.; de Vries, C.; Cook, M.G.; Marks, C.; Topham, C.; Modjtahedi, H. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int. J. Oncol 2004, 24, 241–248.
[37]
Kammula, U.S.; Kuntz, E.J.; Francone, T.D.; Zeng, Z.; Shia, J.; Landmann, R.G.; Paty, P.B.; Weiser, M.R. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007, 248, 219–228.
[38]
Kos, M.; Dabrowski, A. Tumour’s angiogenesis—The function of VEGF and bFGF in colorectal cancer. Ann. Univ. Mariae Curie Sklodowska Med 2002, 57, 556–561.
[39]
Volm, M.; Koomagi, R.; Mattern, J.; Stammler, G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur. J. Cancer 1997, 33, 691–693.
[40]
Katoh, M. Cancer genomics and genetics of FGFR2 (review). Int. J. Oncol 2008, 33, 233–237.
[41]
Rusch, V.; Baselga, J.; Cordon-Cardo, C.; Orazem, J.; Zaman, M.; Hoda, S.; McIntosh, J.; Kurie, J.; Dmitrovsky, E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53, 2379–2385.
[42]
Horstmann, M.; Merseburger, A.S.; von der Heyde, E.; Serth, J.; Wegener, G.; Mengel, M.; Feil, G.; Hennenlotter, J.; Nagele, U.; Anastasiadis, A.; et al. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J. Cancer Res. Clin. Oncol 2005, 131, 715–722.
[43]
Banumathy, G.; Cairns, P. Signaling pathways in renal cell carcinoma. Cancer Biol. Ther 2010, 10, 658–664.
[44]
Yuen, J.S.; Cockman, M.E.; Sullivan, M.; Protheroe, A.; Turner, G.D.; Roberts, I.S.; Pugh, C.W.; Werner, H.; Macaulay, V.M. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007, 26, 6499–6508.
[45]
Kojima, S.; Inahara, M.; Suzuki, H.; Ichikawa, T.; Furuya, Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int. J. Urol 2009, 16, 161–167.
[46]
Neto, A.S.; Tobias-Machado, M.; Wroclawski, M.L.; Fonseca, F.L.; Pompeo, A.C.; del Giglio, A. Molecular oncogenesis of prostate adenocarcinoma: Role of the human epidermal growth factor receptor 2 (HER-2/neu). Tumori 2010, 96, 645–649.
[47]
Kwabi-Addo, B.; Ozen, M.; Ittmann, M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer 2004, 11, 709–724.
[48]
Gravdal, K.; Halvorsen, O.J.; Haukaas, S.A.; Akslen, L.A. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 2006, 448, 68–74.
[49]
Knowles, M.A. Novel therapeutic targets in bladder cancer: Mutation and expression of FGF receptors. Future Oncol 2008, 4, 71–83.
[50]
Black, P.C.; Dinney, C.P. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr. Urol. Rep 2008, 9, 55–61.
[51]
Van Dam, P.A.; Vergote, I.B.; Lowe, D.G.; Watson, J.V.; van Damme, P.; van der Auwera, J.C.; Shepherd, J.H. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J. Clin. Pathol 1994, 47, 914–919.
[52]
Wang, S.C.; Hung, M.C. HER2 overexpression and cancer targeting. Semin. Oncol 2001, 28, 115–124.
[53]
Jin, Q.; Esteva, F.J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13, 485–498.
[54]
Penault-Llorca, F.; Bertucci, F.; Adelaide, J.; Parc, P.; Coulier, F.; Jacquemier, J.; Birnbaum, D.; deLapeyriere, O. Expression of FGF and FGF receptor genes in human breast cancer. Int. J. Cancer 1995, 61, 170–176.
[55]
Marsh, S.K.; Bansal, G.S.; Zammit, C.; Barnard, R.; Coope, R.; Roberts-Clarke, D.; Gomm, J.J.; Coombes, R.C.; Johnston, C.L. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 1999, 18, 1053–1060.
[56]
Easty, D.J.; Gray, S.G.; O’Byrne, K.J.; O’Donnell, D.; Bennett, D.C. Receptor tyrosine kinases and their activation in melanoma. Pigm. Cell Melanoma Res 2011, 24, 446–461.
[57]
Kornmann, M.; Beger, H.G.; Korc, M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 1998, 17, 169–175.
[58]
Scotlandi, K.; Picci, P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr. Opin. Oncol 2008, 20, 419–427.
[59]
Hughes, D.P.; Thomas, D.G.; Giordano, T.J.; Baker, L.H.; McDonagh, K.T. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004, 64, 2047–2053.
[60]
Cottoni, F.; Ceccarelli, S.; Masala, M.V.; Montesu, M.A.; Satta, R.; Pirodda, C.; Rotolo, S.; Frati, L.; Marchese, C.; Angeloni, A. Overexpression of the fibroblast growth factor receptor 2-IIIc in Kaposi’s sarcoma. J. Dermatol. Sci 2009, 53, 65–68.
[61]
Taylor, J.G.T.; Cheuk, A.T.; Tsang, P.S.; Chung, J.Y.; Song, Y.K.; Desai, K.; Yu, Y.; Chen, Q.R.; Shah, K.; Youngblood, V.; et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest 2009, 119, 3395–3407.
[62]
Ribatti, D.; Vacca, A.; Rusnati, M.; Presta, M. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev 2007, 18, 327–334.
[63]
Chesi, M.; Bergsagel, P.L.; Kuehl, W.M. The enigma of ectopic expression of FGFR3 in multiple myeloma: A critical initiating event or just a target for mutational activation during tumor progression. Curr. Opin. Hematol 2002, 9, 288–293.
[64]
Jose, S.; Gotway, G.; Garcia, R.; Vaziri, A.; Tirado, C.A. 8p11–12 FGFR1 rearrangements in hematological malignancies: Review of the literature. J. Assoc. Genet. Technol 2010, 36, 203–208.
[65]
Ronchetti, D.; Greco, A.; Compasso, S.; Colombo, G.; Dell’Era, P.; Otsuki, T.; Lombardi, L.; Neri, A. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): Comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001, 20, 3553–3562.
[66]
Buhring, H.J.; Sures, I.; Jallal, B.; Weiss, F.U.; Busch, F.W.; Ludwig, W.D.; Handgretinger, R.; Waller, H.D.; Ullrich, A. The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood 1995, 86, 1916–1923.
[67]
Hynes, N.E.; MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol 2009, 21, 177–184.
[68]
Voldborg, B.R.; Damstrup, L.; Spang-Thomsen, M.; Poulsen, H.S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol 1997, 8, 1197–1206.
[69]
Hynes, N.E.; Stern, D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1994, 1198, 165–184.
[70]
Baselga, J.; Perez, E.A.; Pienkowski, T.; Bell, R. Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006, 11, S4–S12.
[71]
Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol 2006, 33, 369–385.
[72]
Karamouzis, M.V.; Konstantinopoulos, P.A.; Papavassiliou, A.G. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009, 10, 709–717.
[73]
Ding, S.; Merkulova-Rainon, T.; Han, Z.C.; Tobelem, G. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003, 101, 4816–4822.
[74]
Michieli, P.; Mazzone, M.; Basilico, C.; Cavassa, S.; Sottile, A.; Naldini, L.; Comoglio, P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6, 61–73.
[75]
Birchmeier, C.; Birchmeier, W.; Gherardi, E.; van de Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol 2003, 4, 915–925.
[76]
Ido, A.; Tsubouchi, H. Translational research to identify clinical applications of hepatocyte growth factor. Hepatol. Res 2009, 39, 739–747.
[77]
Ponzo, M.G.; Lesurf, R.; Petkiewicz, S.; O’Malley, F.P.; Pinnaduwage, D.; Andrulis, I.L.; Bull, S.B.; Chughtai, N.; Zuo, D.; Souleimanova, M.; et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. USA 2009, 106, 12903–12908.
[78]
Pacher, M.; Seewald, M.J.; Mikula, M.; Oehler, S.; Mogg, M.; Vinatzer, U.; Eger, A.; Schweifer, N.; Varecka, R.; Sommergruber, W.; et al. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis 2007, 28, 49–59.
[79]
Pollak, M.N.; Schernhammer, E.S.; Hankinson, S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4, 505–518.
[80]
Yee, D. The insulin-like growth factor system as a treatment target in breast cancer. Semin. Oncol 2002, 29, 86–95.
[81]
Roberts, C.T., Jr. Control of insulin-like growth factor (IGF) action by regulation of IGF-I receptor expression. Endocr. J 1996, 43, S49–S55.
[82]
Lu, Y.; Zi, X.; Zhao, Y.; Mascarenhas, D.; Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst 2001, 93, 1852–1857.
[83]
Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med 1995, 1, 27–31.
[84]
Folkman, J. Tumor angiogenesis. Adv. Cancer Res 1985, 43, 175–203.
[85]
Distler, J.H.; Hirth, A.; Kurowska-Stolarska, M.; Gay, R.E.; Gay, S.; Distler, O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med 2003, 47, 149–161.
[86]
Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med 2003, 9, 669–676.
[87]
Ortega, N.; Hutchings, H.; Plouet, J. Signal relays in the VEGF system. Front. Biosci 1999, 4, D141–D152.
[88]
Roy, H.; Bhardwaj, S.; Yla-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett 2006, 580, 2879–2887.
[89]
Otrock, Z.K.; Makarem, J.A.; Shamseddine, A.I. Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol. Dis 2007, 38, 258–268.
Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307, 58–62.
[92]
Tortora, G.; Melisi, D.; Ciardiello, F. Angiogenesis: A target for cancer therapy. Curr. Pharm. Des 2004, 10, 11–26.
[93]
Hurwitz, H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin. Colorectal Cancer 2004, 4, S62–S68.
[94]
Lu, D.; Shen, J.; Vil, M.D.; Zhang, H.; Jimenez, X.; Bohlen, P.; Witte, L.; Zhu, Z. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem 2003, 278, 43496–43507.
[95]
Cooke, S.P.; Boxer, G.M.; Lawrence, L.; Pedley, R.B.; Spencer, D.I.; Begent, R.H.; Chester, K.A. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex. Cancer Res 2001, 61, 3653–3659.
[96]
Vitaliti, A.; Wittmer, M.; Steiner, R.; Wyder, L.; Neri, D.; Klemenz, R. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res 2000, 60, 4311–4314.
Basilico, C.; Moscatelli, D. The FGF family of growth factors and oncogenes. Adv. Cancer Res 1992, 59, 115–165.
[99]
Folkman, J.; Shing, Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol 1992, 313, 355–364.
[100]
Presta, M.; Moscatelli, D.; Joseph-Silverstein, J.; Rifkin, D.B. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol. Cell. Biol 1986, 6, 4060–4066.
[101]
Javerzat, S.; Auguste, P.; Bikfalvi, A. The role of fibroblast growth factors in vascular development. Trends Mol. Med 2002, 8, 483–489.
[102]
Powers, C.J.; McLeskey, S.W.; Wellstein, A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 2000, 7, 165–197.
[103]
Johnson, D.E.; Williams, L.T. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res 1993, 60, 1–41.
[104]
Giri, D.; Ropiquet, F.; Ittmann, M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res 1999, 5, 1063–1071.
[105]
Antoine, M.; Wirz, W.; Tag, C.G.; Mavituna, M.; Emans, N.; Korff, T.; Stoldt, V.; Gressner, A.M.; Kiefer, P. Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors 2005, 23, 87–95.
[106]
Ronca, R.; Benzoni, P.; Leali, D.; Urbinati, C.; Belleri, M.; Corsini, M.; Alessi, P.; Coltrini, D.; Calza, S.; Presta, M.; et al. Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol. Cancer Ther 2010, 9, 3244–3253.
[107]
Yayon, A.; Aviezer, D.; Safran, M.; Gross, J.L.; Heldman, Y.; Cabilly, S.; Givol, D.; Katchalski-Katzir, E. Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. Proc. Natl. Acad. Sci. USA 1993, 90, 10643–10647.
[108]
Cardo-Vila, M.; Giordano, R.J.; Sidman, R.L.; Bronk, L.F.; Fan, Z.; Mendelsohn, J.; Arap, W.; Pasqualini, R. From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway. Proc. Natl. Acad. Sci. USA 2010, 107, 5118–5123.
[109]
Kumar, S.R.; Quinn, T.P.; Deutscher, S.L. Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin. Cancer Res 2007, 13, 6070–6079.
[110]
Hetian, L.; Ping, A.; Shumei, S.; Xiaoying, L.; Luowen, H.; Jian, W.; Lin, M.; Meisheng, L.; Junshan, Y.; Chengchao, S. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J. Biol. Chem 2002, 277, 43137–43142.
[111]
Rastelli, L.; Valentino, M.L.; Minderman, M.C.; Landin, J.; Malyankar, U.M.; Lescoe, M.K.; Kitson, R.; Brunson, K.; Souan, L.; Forenza, S.; et al. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo. Int. J. Oncol 2011, 39, 401–408.
Binetruy-Tournaire, R.; Demangel, C.; Malavaud, B.; Vassy, R.; Rouyre, S.; Kraemer, M.; Plouet, J.; Derbin, C.; Perret, G.; et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000, 19, 1525–1533.
[115]
Nilsson, F.; Tarli, L.; Viti, F.; Neri, D. The use of phage display for the development of tumour targeting agents. Adv. Drug Deliv. Rev 2000, 43, 165–196.
[116]
Yoo, M.K.; Kang, S.K.; Choi, J.H.; Park, I.K.; Na, H.S.; Lee, H.C.; Kim, E.B.; Lee, N.K.; Nah, J.W.; Choi, Y.J.; et al. Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique. Biomaterials 2010, 31, 7738–7747.
[117]
Laakkonen, P.; Akerman, M.E.; Biliran, H.; Yang, M.; Ferrer, F.; Karpanen, T.; Hoffman, R.M.; Ruoslahti, E. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101, 9381–9386.
[118]
Zhu, Z.; Rockwell, P.; Lu, D.; Kotanides, H.; Pytowski, B.; Hicklin, D.J.; Bohlen, P.; Witte, L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998, 58, 3209–3214.
Veggiani, G.; Ossolengo, G.; Aliprandi, M.; Cavallaro, U.; de Marco, A. Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1. Biochem. Biophys. Res. Commun 2011, 408, 692–696.
[121]
Dong, J.; Sereno, A.; Aivazian, D.; Langley, E.; Miller, B.R.; Snyder, W.B.; Chan, E.; Cantele, M.; Morena, R.; Joseph, I.B.; et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011, 3, 273–288.
[122]
Lu, R.M.; Chang, Y.L.; Chen, M.S.; Wu, H.C. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 2011, 32, 3265–3274.
[123]
Lee, J.W.; Stone, R.L.; Lee, S.J.; Nam, E.J.; Roh, J.W.; Nick, A.M.; Han, H.D.; Shahzad, M.M.; Kim, H.S.; Mangala, L.S.; et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin. Cancer Res 2010, 16, 2562–2570.
[124]
LoRusso, P.M.; Weiss, D.; Guardino, E.; Girish, S.; Sliwkowski, M.X. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res 2011, 17, 6437–6447.
[125]
Moldenhauer, G.; Salnikov, A.V.; Luttgau, S.; Herr, I.; Anderl, J.; Faulstich, H. Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma. J. Natl. Cancer Inst 2012, doi:10.1093/jnci/djs140.
[126]
Green, L.L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 1999, 231, 11–23.
[127]
Lonberg, N. Fully human antibodies from transgenic mouse and phage display platforms. Curr. Opin. Immunol 2008, 20, 450–459.
[128]
Louis, E.; Lofberg, R.; Reinisch, W.; Camez, A.; Yang, M.; Pollack, P.F.; Chen, N.; Chao, J.; Mulani, P.M. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn;s disease: Results from the CARE trial. J. Crohns Colitis 2012, doi:10.1016/j.crohns.2012.02.017.
[129]
Yang, H.; Epstein, D.; Bojke, L.; Craig, D.; Light, K.; Bruce, I.; Sculpher, M.; Woolacott, N. Golimumab for the treatment of psoriatic arthritis. Health Technol. Assess 2011, 15, S87–S95.
[130]
Ballestrero, A.; Garuti, A.; Cirmena, G.; Rocco, I.; Palermo, C.; Nencioni, A.; Scabini, S.; Zoppoli, G.; Parodi, S.; Patrone, F. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr. Cancer Drug Targets 2012, 12, 316–328.
[131]
Curran, M.P. Canakinumab: In patients with cryopyrin-associated periodic syndromes. BioDrugs 2012, 26, 53–59.
[132]
Winchester, D.; Callis Duffin, K.; Hansen, C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic discoid lupus. Lupus 2012, doi:10.1177/0961203312441982.
[133]
Hoyle, M.; Crathorne, L.; Garside, R.; Hyde, C. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: A critique of the submission from GSK. Health Technol. Assess 2011, 15, S61–S67.
[134]
Waugh, N.; Royle, P.; Scotland, G.; Henderson, R.; Hollick, R.; McNamee, P. Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Health Technol. Assess 2011, 15, S51–S59.
[135]
Boyce, E.G.; Fusco, B.E. Belimumab: Review of use in systemic lupus erythematosus. Clin. Ther 2012, doi:10.1016/j.clinthera.2012.02028.
[136]
Margolin, K.; Ernstoff, M.S.; Hamid, O.; Lawrence, D.; McDermott, D.; Puzanov, I.; Wolchok, J.D.; Clark, J.I.; Sznol, M.; Logan, T.F.; et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 2012, ((12)), 70090–6, doi:10.1016/S1470-2045.
[137]
Cameron, F.; Whiteside, G.; Perry, C. Ipilimumab: First global approval. Drugs 2011, 71, 1093–1104.
[138]
Migone, T.S.; Subramanian, G.M.; Zhong, J.; Healey, L.M.; Corey, A.; Devalaraja, M.; Lo, L.; Ullrich, S.; Zimmerman, J.; Chen, A.; et al. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med 2009, 361, 135–144.
Rowinsky, E.K.; Youssoufian, H.; Tonra, J.R.; Solomon, P.; Burtrum, D.; Ludwig, D.L. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res 2007, 13, 5549s–5555s.
[141]
Erinjeri, J.P.; Deodhar, A.; Thornton, R.H.; Allen, P.J.; Getrajdman, G.I.; Brown, K.T.; Sofocleous, C.T.; Reidy, D.L. Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver. Cardiovasc. Intervent. Radiol 2010, 33, 610–614.
[142]
Beltran, P.J.; Mitchell, P.; Chung, Y.A.; Cajulis, E.; Lu, J.; Belmontes, B.; Ho, J.; Tsai, M.M.; Zhu, M.; Vonderfecht, S.; et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther 2009, 8, 1095–1105.
[143]
Tolcher, A.W.; Sarantopoulos, J.; Patnaik, A.; Papadopoulos, K.; Lin, C.C.; Rodon, J.; Murphy, B.; Roth, B.; McCaffery, I.; Gorski, K.S.; et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol 2009, 27, 5800–5807.
[144]
Beltran, P.J.; Chung, Y.A.; Moody, G.; Mitchell, P.; Cajulis, E.; Vonderfecht, S.; Kendall, R.; Radinsky, R.; Calzone, F.J. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing’s and osteogenic sarcoma models. J. Pharmacol. Exp. Ther 2011, 337, 644–654.
[145]
Tammela, T.; Zarkada, G.; Wallgard, E.; Murtomaki, A.; Suchting, S.; Wirzenius, M.; Waltari, M.; Hellstrom, M.; Schomber, T.; Peltonen, R.; et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454, 656–660.
[146]
Kuenen, B.; Witteveen, P.O.; Ruijter, R.; Giaccone, G.; Dontabhaktuni, A.; Fox, F.; Katz, T.; Youssoufian, H.; Zhu, J.; Rowinsky, E.K.; et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin. Cancer Res 2010, 16, 1915–1923.
[147]
Lu, D.; Jimenez, X.; Zhang, H.; Bohlen, P.; Witte, L.; Zhu, Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int. J. Cancer 2002, 97, 393–399.
[148]
Karkkainen, M.J.; Jussila, L.; Ferrell, R.E.; Finegold, D.N.; Alitalo, K. Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol. Med 2001, 7, 18–22.
[149]
Achen, M.G.; Stacker, S.A. Molecular control of lymphatic metastasis. Ann. NY Acad. Sci 2008, 1131, 225–234.
[150]
Grau, S.J.; Trillsch, F.; Herms, J.; Thon, N.; Nelson, P.J.; Tonn, J.C.; Goldbrunner, R. Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J. Neurooncol 2007, 82, 141–150.
[151]
Hajrasouliha, A.R.; Funaki, T.; Sadrai, Z.; Hattori, T.; Chauhan, S.K.; Dana, R. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci 2012, 53, 1244–1250.
[152]
Grutter, C.; Wilkinson, T.; Turner, R.; Podichetty, S.; Finch, D.; McCourt, M.; Loning, S.; Jermutus, L.; Grutter, M.G. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc. Natl. Acad. Sci. USA 2008, 105, 20251–20256.
[153]
Ronca, R.; Sozzani, S.; Presta, M.; Alessi, P. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case. Immunobiology 2009, 214, 800–810.
[154]
Kurtz, J.E.; Dufour, P. Adecatumumab: An anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin. Biol. Ther 2010, 10, 951–958.
[155]
Casi, G.; Neri, D. Antibody-drug conjugates: Basic concepts, examples and future perspectives. J. Control. Release 2012, doi:10.1016/j.jconrel.2012.01.026.
